Shots:
- The P-II clinical trial involves evaluating ASP377 (a novel 24 valent MAPS Vaccine) vs Prevnar 13 & Pneumovax 23 in 503 adults aged 65-85yrs. with Streptococcus pneumoniae. The vaccine was developed using Affinivax’s MAPS platform technology
- The results showed that the ASP3772 was well tolerated, induced a robust immune response in 24 pneumococcal serotypes in MAPS vaccine as measured by IgG & OPA & showed an increase in Abs response to the conserved pneumococcal proteins
- ASP3772 has also received FDA’s BTD in adults aged >50 yrs. for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes, based on P-II results
Click here to read full press release/ article | Ref: Astellas | Image: Financial Times
The post Astellas and Affinivax Present Results of ASP3772 in P-II Study for Streptococcus Pneumoniae first appeared on PharmaShots.
